Our pipeline

Product candidate
Cancer Indication
Combination with
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Pemetrexed/
cisplatin
KEYTRUDA®
ONCOS-102
Peritoneal
ODD*
IMFINZI® (Collab. with: Ludwig, CRI & AZ)
ONCOS-102
Prostate
DCVAC (Collab. with: SOTIO)
Undisclosed
-
Gemcitabine
KEYTRUDA®
TG02
CPI synergy
TG + PD-1
Cancer Indication: Mesothelioma ODD
Combination with: Pemetrexed/
cisplatin

Product candidate: ONCOS-102
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Melanoma
Combination with: KEYTRUDA®
Product candidate: ONCOS-102
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Peritoneal
ODD*

Combination with: IMFINZI® (Collab. with: Ludwig, CRI & AZ)
Product candidate: ONCOS-102
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Prostate
Combination with: DCVAC (Collab. with: SOTIO)
Product candidate: ONCOS-102
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Undisclosed
Combination with: -
Product candidate: ONCOS-X02
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Resected Panceras
Combination with: Gemcitabine
Product candidate: TG01
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Colorectal
Combination with: KEYTRUDA®
Product candidate: TG02
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication:
Combination with: CPI synergy
TG + PD-1

Product candidate: TG02
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Ongoing collaborator sponsored trials

ODD=Orphan Drug Indication
ODD*=ODD in Ovarian Cancer Perioteneal Subpopulation